Worksheet No. NRP-022A.doc

Worksheet author

Ruth Guinsburg

Date Submitted for review: October 3, 2009

Clinical question.

In apneic neonates suspected of narcotic depression (P), does naloxone (I) when compared to effective ventilation without naloxone (C) improve outcome (O)?

Is this question addressing an intervention/therapy, prognosis or diagnosis? **Intervention/therapy**

State if this is a proposed new topic or revision of existing worksheet: **Revision**

Conflict of interest specific to this question

Do any of the authors listed above have conflict of interest disclosures relevant to this worksheet?

**Search strategy (including electronic databases searched).**

Strategy for searches without any limit of period:

1. Medline - ("naloxone"[MeSH Terms] OR "naloxone"[All Fields]) AND "infant, newborn"[MeSH Terms]): 189 references.
2. Medline - ("narcotic antagonists"[MeSH Terms] OR ("narcotic"[All Fields] AND "antagonists"[All Fields]) OR "narcotic antagonists"[All Fields] OR "narcotic antagonists"[Pharmacological Action]) AND "infant, newborn"[MeSH Terms]): 312 references
3. Embase - 'naloxone'/exp/mj AND [newborn]/lim AND [embase]/lim: 331 references
4. SciELO ([www.scielo.br](http://www.scielo.br)) - Naloxone [Term] in all indexes (regional): 35 references
5. NICHD Cochrane Neonatal – Naloxone [Term]: 5 references
6. ECC Master library: “naloxone” and “infant” [Terms in Abstract]: 21 references
7. Eligible articles in reference lists of all articles that met inclusion criteria

**State inclusion and exclusion criteria**

**Inclusion criteria:**

1. Case reports, case series, cross-sectional, prospective or retrospective cohorts, clinical trials, systematic reviews and meta-analysis that analyzed the use of naloxone in the delivery room for depressed infants at birth and/or for infants of mothers that received opioids prior to delivery.
2. Animal studies that evaluate effects and side-effects of naloxone with neonatal models.
3. Human studies that evaluate possible side effects of naloxone in pediatrics

**Exclusion criteria:**

Naloxone studies in any age groups beyond neonatal period (except for possible side effects) and comments or personal opinions.

**Number of articles/sources meeting criteria for further review:**

The following studies about naloxone use were retrieved:
- 12 studies of narcotic exposed infants but they were not necessarily depressed or apneic at birth. These included 2 meta-analyses (the same meta-analysis published both in Cochrane review and Arch Dis Child Fetal Neonatal Ed)
- 7 studies on depressed infants or animals at birth not exposed to narcotics prior to delivery. These included 1 meta-analysis, 2 clinical and 4 animal studies.
- 3 studies with infants exposed to maternal opioids and depressed at birth. All 3 studies were observational studies about frequency of naloxone use for neonatal resuscitation in the delivery room.
- 1 experimental study with animals not exposed to maternal opioids and not depressed at birth.
- 6 studies about possible side effects of naloxone use in pediatric patients: 3 case reports, 1 cohort and 2 animal studies.
- 1 in vitro study regarding the effect of naloxone on immature endothelial cells.
- 1 systematic review of available information on possible benefits of Naloxone use in neonatal resuscitation in the delivery room resulting from 2005 ILCOR evidence review process.

Observation: Literature search of all databases was done again at October 1st, 2009 with the same strategy described above but restricted to the six months. 2 new studies were retrieved retrieved but none had relevant information to be added.

**Therefore, 31 studies are included in the evaluation process.**
## Summary of evidence

### Evidence Supporting Clinical Question:

<table>
<thead>
<tr>
<th>Level of evidence</th>
<th>Evidence Supporting Clinical Question</th>
</tr>
</thead>
</table>

E = Other endpoint; *Italics* = Animal studies
* narcotic exposed infants or animals, but not necessarily depressed at birth
** depressed infants or animals at birth not exposed to narcotics prior to delivery
*** depressed infants or animals at birth and exposed to narcotics prior to delivery
**** not depressed infants or animals at birth and exposed to narcotics prior to delivery
& other

### Evidence Neutral to Clinical Question:

<table>
<thead>
<tr>
<th>Level of evidence</th>
<th>Evidence Neutral to Clinical Question</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fair</td>
<td>[Herschel, 2000, 831-4]**</td>
</tr>
<tr>
<td>Poor</td>
<td></td>
</tr>
</tbody>
</table>

E = Other endpoint; *Italics* = Animal studies
* narcotic exposed infants or animals, but not necessarily depressed at birth
** depressed infants or animals at birth not exposed to narcotics prior to delivery
*** depressed infants or animals at birth and exposed to narcotics prior to delivery
**** not depressed infants or animals at birth and exposed to narcotics prior to delivery
& other
## Evidence Opposing Clinical Question

<table>
<thead>
<tr>
<th>Level of Evidence</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Good</strong></td>
<td>[Bonta, 1979, 102-5]*E</td>
</tr>
<tr>
<td></td>
<td>[Laudenbach, 2001, 457-66]**E</td>
</tr>
<tr>
<td></td>
<td>[Chernick, 1988, 519-25]**E</td>
</tr>
<tr>
<td></td>
<td>[de-Castro, 1993, 747-51]*****E</td>
</tr>
<tr>
<td></td>
<td>[Gill and Colvin, 2007, 795-8]***E</td>
</tr>
<tr>
<td></td>
<td>[Box and Cochran, 2006, 1083-6]***E</td>
</tr>
<tr>
<td></td>
<td>[Padbury, 1987, 590-3]*****E</td>
</tr>
<tr>
<td></td>
<td>[Martinez, 1988, 343-7]******E</td>
</tr>
<tr>
<td><strong>Fair</strong></td>
<td>[Dick, 1978, 95-110]*E</td>
</tr>
<tr>
<td></td>
<td>[Welles, 1984, 617-9]*E</td>
</tr>
<tr>
<td></td>
<td>[Young, 1984, 52-6]**E</td>
</tr>
<tr>
<td><strong>Poor</strong></td>
<td>[Deshpande and Gill, 2009, 115-7] *****E</td>
</tr>
<tr>
<td></td>
<td>[Gibbs, 1989, 159-60]*****E</td>
</tr>
<tr>
<td></td>
<td>[Johnson, 1995, 356-7]*****E</td>
</tr>
<tr>
<td></td>
<td>[Prough, 1984, 485-6]*****E</td>
</tr>
<tr>
<td></td>
<td>[Hasan, 2003, 1587-92]*****E</td>
</tr>
</tbody>
</table>

**E = Other endpoint; Italics = Animal studies**

* narcotic exposed infants or animals, but not necessarily depressed at birth
** depressed infants or animals at birth not exposed to narcotics prior to delivery
*** depressed infants or animals at birth and exposed to narcotics prior to delivery
**** not depressed infants or animals at birth and exposed to narcotics prior to delivery
***** non-newborn infants with side effects related to naloxone administration
**REVIEWER’S FINAL COMMENTS AND ASSESSMENT OF BENEFIT / RISK:**

Since the last revision [Guinsburg and Wyckoff, 2006, 121-32, viii] no substantial studies were added to the literature. There are no studies comparing neonatal outcomes after the administration of naloxone versus positive pressure ventilation for newborn infants apneic at birth. There is not a single study evaluating the efficacy of naloxone in reversing respiratory depression at birth in babies exposed to opioids prior to delivery. Evidence does exist to indicate that for infants with good respiratory effort despite maternal opiate exposure, subtle measures of respiration are increased at least for a short period of time after administration of naloxone with enhanced alveolar ventilation in the first 30 minutes after drug administration and improved CO₂ response curves (LOE 5) [Brice, Moreland, 1979, 356-61] [Chernick and Craig, 1982, 1252-3] [Chernick, Madansky, 1980, 357-9] [Evans, Hogg, 1976, 1098-100] [Gerhardt, Bancalari, 1977, 1009-12] [Wiener, Hogg, 1977, 229-31] [Wiener, Hogg, 1977, 228-9]. But, there are no studies that address clinically relevant endpoints such decreased need for prolonged ventilation in the delivery room and/or admission to the neonatal intensive care unit [McGuire and Fowlie, 2002, CD003483] [McGuire and Fowlie, 2003, F308-11]. On the other hand, some observational studies show a steady decrease in naloxone use in the delivery room for narcotic exposed newborn infants without concurrent increase in morbidity (LOE 5) [Box and Cochran, 2006, 1083-6] [Gill and Colvin, 2007, 795-8]. Although there is some evidence of improved short term behavioral assessment in narcotic exposed neonates that receive naloxone at birth, these effects do no last long and their clinical relevance is questionable (LOE 5) [Hodgkinson, Bhatt, 1978, 294-8] [McGuire, Fowlie, 2004, CD003955]. Animal data and sparse case reports in neonates and pediatric patients raise concerns about direct myocardial depression [Deshpande and Gill, 2009, 115-7] or catecholamine surge after the use of high doses of naloxone, increasing sympathetic nervous system activity, which may result in cardiac arrhythmias, hypertension and non-cardiogenic pulmonary edema (LOE 5) [Martinez, Padbury, 1988, 343-7] [Padbury, Agata, 1987, 590-3] [Hasan, Benko, 2003, 1587-92] [Johnson, Mayer, 1995, 356-7] [Prough, Roy, 1984, 485-6]. Some very limited animal information raises questions about long term effects of naloxone regarding the potential to increase neuronal and/or white matter and/or endothelial damage in asphyxiated patients (LOE 5) [Laudenbach, Calo, 2001, 457-66] [Van Woerkom, Beharry, 2004, 147-51], and regarding modifications in pain responsiveness during life (LOE 5) [de-Castro, Cabral-Filho, 1993, 747-51]. The concern for precipitating seizures due rapid withdrawal is based on one case report (LOE 5) [Gibbs, Newson, 1989, 159-60].

**Acknowledgements:**
Citation List


   Research notes:
   LOE 5 opposing; randomized control trial; the study does not compare naloxone and PPV; neonates were not necessarily depressed/apneic at birth.


   Research notes:
   LOE 5 opposing; retrospective and prospective cohort study; the study does not compare naloxone and PPV; the study addresses practices and not outcomes.


   Research notes:
   LOE 5 supporting; randomized control trial with some methodological problems; the study does not compare naloxone and PPV; neonates were not necessarily depressed/apneic at birth.


   Research notes:
   LOE 5 supporting; animal study that does not compare naloxone and PPV; depressed newborns were not exposed to opioids before birth.


   Research notes:
   LOE 5 supporting; animal study that does not compare naloxone and PPV; depressed newborns were not exposed to opioids before birth.


   Research notes:
   LOE 5 opposing; animal study that does not compare naloxone and PPV; depressed newborns were not exposed to opioids before birth.

Research notes:
LOE 5 opposing; animal study that does not compare naloxone and PPV; newborn animals were not exposed to opioids before birth and were not depressed/apneic at birth.


Research notes:
LOE 5 opposing; case report of a premature infant that had serious side effects after naloxone use to reverse morphine overdosing.


Research notes:
LOE 5 opposing; randomized control trial with some methodological problems; the study does not compare naloxone and PPV; neonates were not necessarily depressed/apneic at birth.


Research notes:
LOE 5 supporting; case series? The study does not compare naloxone and PPV; neonates were not necessarily depressed/apneic at birth.


Research notes:
LOE 5 supporting; case series? The study does not compare naloxone and PPV; neonates were not necessarily depressed/apneic at birth.


Research notes:
LOE 5 opposing; case report of an infant born to an opioid abuser mother that had seizures after naloxone administration.


Research notes:
LOE 5 opposing; retrospective and prospective cohort study; the study does not compare naloxone and PPV; the study addresses practices and not outcomes.

Research notes:
Systematic review regarding evidence retrieved for 2005 ILCOR Consensus on Science. LOE not attributed since it was not used either to refute or to support the clinical question.


Research notes:
LOE 5 opposing; cohort of pediatric patients reporting effectiveness and safety of naloxone treatment.


Research notes:
LOE 5 neutral; retrospective and prospective cohort study; the study does not compare naloxone and PPV; the study addresses practices and not outcomes.


Research notes:
LOE 5 supporting; randomized controlled clinical trial; The study does not compare naloxone and PPV; neonates were not necessarily depressed/apneic at birth.


Research notes:
LOE 5 opposing; case report of a teenager female healthy patient that had serious side effects after post-operative naloxone use.


Research notes:
LOE 5 opposing; animal study that does not compare naloxone and PPV; depressed newborn animals were not exposed to opioids before birth.


Research notes:
LOE 5 opposing; animal study that does not compare naloxone and PPV; sympahoadrenal response in hypoxic newborn lambs with naloxone use.

Research notes:
LOE 5 neutral; meta-analysis, but comprises studies that do not compare naloxone and PPV; neonates were not necessarily depressed/apneic at birth.


Research notes:
LOE 5 neutral; meta-analysis, but comprises studies that do not compare naloxone and PPV; neonates were not necessarily depressed/apneic at birth. Same meta-analysis as above published in a different place.


Research notes:
LOE 5 neutral; meta-analysis, but comprises studies that do not compare naloxone and PPV; neonates were necessarily depressed/apneic at birth, but were not exposed to opioids before at labor or delivery.


Research notes:
LOE 5 opposing; animal study that does not compare naloxone and PPV; sympathoadrenal response in hypoxic newborn lambs with naloxone use.


Research notes:
LOE 5 opposing; case report of two teenager patients that had serious side effects after naloxone use.


Research notes:
LOE 5 supporting; animal study that does not compare naloxone and PPV; depressed newborn animals were not exposed to opioids before birth.


Research notes:
LOE 5 neutral; in vitro study with immature cultured endothelial cells; it does not compare naloxone and PPV.

Research notes: LOE 5 opposing; randomized clinical trial (powerless); the study does not compare naloxone and PPV; neonates were not necessarily depressed/apneic at birth.


Research notes:
LOE 5 supporting; randomized clinical trial (powerless); the study does not compare naloxone and PPV; neonates were not necessarily depressed/apneic at birth.


Research notes:
LOE 5 supporting; randomized clinical trial (powerless); the study does not compare naloxone and PPV; neonates were not necessarily depressed/apneic at birth.


Research notes:
LOE 5 opposing; animal study that does not compare naloxone and PPV; depressed newborn animals were not exposed to opioids before birth.